Literature DB >> 27494778

Surgical Treatment of Subretinal Fibrosis Caused Macular Detachment in Vogt-Koyanagi-Harada Disease: A Pioneer Study.

Chan Zhao1, Meifen Zhang1, Fei Gao1, Fangtian Dong1.   

Abstract

PURPOSE: To describe surgical outcomes of macular detachment caused by subretinal fibrosis (SRF) in Vogt-Koyanagi-Harada disease (VKH).
METHODS: Retrospective review of VKH patients who underwent SRF removal surgery.
RESULTS: Seven eyes of six VKH patients with preoperative BCVA ranging from light perception to 20/250 were included. Six eyes underwent uncomplicated SRF removal with C3F8 or silicone oil (SO) tamponade and the following optional primary or subsequent procedures: intravitreal injection of triamcinolone acetonide, SO removal, lensectomy, or phacoemulsification with intraocular lens (IOL) implantation. All six eyes had attached macula and improved BCVA at the last visit (ranging from 20/2000 to 20/67) compared to baseline; the other eye, however, showed no light perception after surgery due to optic nerve injury.
CONCLUSIONS: In VKH patients, macular detachment caused by SRF can be treated with surgery with generally favorable outcomes. Extreme caution should be taken to avoid optic nerve injury.

Entities:  

Keywords:  Macular detachment; Vogt-Koyanagi-Harada disease; spectral domain optical coherence tomography; subretinal fibrosis; surgery

Mesh:

Substances:

Year:  2016        PMID: 27494778     DOI: 10.1080/09273948.2016.1201519

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Vogt-Koyanagi-Harada Syndrome in a Ugandan: Diagnostic and Therapeutic Challenges.

Authors:  Felix Bongomin; Francis S Onen; Mark Kaddumukasa
Journal:  Case Rep Med       Date:  2019-09-16

2.  Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.

Authors:  Chan Zhao; Fangtian Dong; Fei Gao; Xinshu Liu; Minghang Pei; Shanshan Jia; Meifen Zhang
Journal:  BMC Ophthalmol       Date:  2018-01-15       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.